business
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
Read full story on MarketWatch → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from MarketWatch alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop